| Ytd | 67.18% | |
| 1y | 106.26% |
| Open | 26.98 | Prev Close | 26.99 | Low | 26.98 | High | 27.00 | Mkt Cap | 1.44B |
| Vol | 0.00 | Avg Vol | 3.63M | EPS | -3.94 | P/E | -6.85 | Forward P/E | 25.45 |
| Beta | -0.12 | Short Ratio | 0.94 | Inst. Own | 136.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 24.43 | 200-d Avg | 17.09 | 1yr Est | 27.00 |
KALV News
PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international researc
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optim
This clinical-stage biotech focused on rare diseases reported a notable insider sale amid a year of
[url="]KalVista Pharmaceuticals[/url], Inc. (Nasdaq: KALV) today announced new data highlighting the
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KAL
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbe
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender t
MILWAUKEE, April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista (NASDAQ: KALV) for pos
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde a
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale
U.S. stocks lower, Dow Jones down 200 points. General Dynamics shares rise after better-than-expecte
Italy's Chiesi has agreed to buy KalVista Pharmaceuticals for about $1.9 billion, the company
PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international researc
Italian pharma company Chiesi Group will buy U.S.-listed KalVista Pharmaceuticals in an all-cash dea
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) insider Paul Audhya sold 2,686 share
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) insider Nicole Sweeny sold 1,862 sha
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) CFO Brian Piekos sold 1,862 shares o
KalVista Pharmaceuticals (NASDAQ: KALV) CEO Ben Palleiko told investors at Needham and Company's 25t
During Wednesday's trading, 517 companies set new 52-week lows.
On Friday, 404 stocks made new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 216 stocks hit new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Thursday